Background: Phase III randomized controlled trials (RCTs) are the cornerstone of evidence-based oncology. However, there is no exhaustive review describing the radiotherapy RTCs characteristics. The objective of the present study was to describe features of all phase III RCTs including at least a radiation therapy.
Introduction
Evidence-based oncology is founded on information provided by clinical trials. Randomized clinical trials (RCTs) procure the highest level of evidence and lead the way to new anticancer treatments [1] . Phase I clinical studies are designed to assess the safety profile of therapies. Phase II trials evaluate the therapeutic index (efficacy/toxicity ratio), allowing therapies to be further investigated or not. Phase III studies are designed to compare experimental treatments versus gold standards, either to prove equivalence or superiority. Toxicity reporting through standardized scales is also a major end point, highlighting acute and late toxicities of experimental therapeutic programs [2] .
The benefit of innovative radiotherapy (RT) techniques should theoretically be proven in phase III randomized studies. However, since radiotherapy does not meet the same prescription rules as oncologic drugs, modern techniques [intensity modulated radiotherapy (IMRT), volumetric modulated arc-therapy (VMAT), stereotactic body radiotherapy (SBRT), etc.] were implemented without a clear knowledge of their therapeutic index [3] . To our best knowledge, an exhaustive literature review describing the essential characteristics of radiotherapy phase III trials has never been carried out. Yet, this is the only way to know what radiation practices were validated in randomized phase III studies. Furthermore, the identification of patient characteristics and of main trials' biases are necessary conditions to be able to criticize their methodology and respect their limits [4, 5] . Finally, an update on what has been accomplished in phase III radiotherapy trials would help to identify the future challenges of radiation oncology research.
The aim of the present study was to describe and analyze all randomized phase III clinical trials including at least a radiation therapy.
Methods and materials
Requests were performed in the Medline database (via PubMed) to identify all publications of phase III RCTs analyzing radiation therapy between 1993 (first RCT) and 2016. The latest update was performed in April 2016, using the following MESH terms: 'clinical trials: phase III as topic', 'radiotherapy', 'brachytherapy', as keywords and 'English' as limit. Reviewing lists of reported RCT from large cooperative groups such as EOTRC, NSABP, RTOG, SWOG, NCIC, TROG and GORTEC were analyzed to ensure major studies have not been omitted. References were crossed with clinicaltrials.gov to identify RCT noting some older trials that could have not been included in such registries.
Study selection
Phase III trials were eligible for inclusion if cancer patients (including malignant blood diseases) were prospectively recruited and if at least one of the randomly assigned treatment included radiotherapy and/or brachytherapy. Exclusion criteria were: radiopharmaceutical trials, non-randomized design, absence of available full text, and sole abstracts. In case of several publications for the same trial, only most recent data were considered. A first selection was conducted based on title and abstract. Then eligible articles were selected on full text and reviewed. Selections were carried out independently by two reviewers. Concordant articles were included in analysis by the first reviewer and disagreements between the two selections were resolved by a third reviewer.
Data collection
For each selected trial, two different reviewers collected the following data: journal's name, year of publication, number of participating centers (mono/multicenter study), design of the study (open versus double-blind; superiority versus non-inferiority), intention to treat analysis (ITT) (yes/no), median follow up, primary end point (overall survival, progression-free survival, disease-free survival, distant progression, local control, biochemical failure, toxicity, quality of life, pain palliation), experimental hypothesis, number of included patients, cancer(s) type, stage (early disease, locally advanced, metastasis), median age, radiotherapy fractionation (standard fractionation: 1.8-2.2 Gy), radiotherapy technique, radiotherapy dose escalation (yes/no), concurrent chemotherapy (CT) administration (yes/no), cytotoxic agents' name, concurrent non-cytotoxic agent (NCA: including targeted therapies, immunotherapies, hormonotherapies and other agents such as radiosensitizing or radioprotective agents) administration (yes/no), NCA name, acute all grades and acute grade 3-5 toxicities [yes/no, evaluated by the National Cancer Institute Common Toxicity Criteria (CTCAE v3.0)], late (>3 months) toxicities (yes/ no), quality of life (yes/no) and industrial sponsorship.
Statistical analysis
A descriptive analysis of the results was realized. Median values were given with their interquartile ranges and their minimum and maximum values.
Results

Literature selection
Initial research resulted in 1254 hits. After a first selection on title and abstract, 707 full-text reports were assessed for eligibility. After duplicates suppression, 454 studies met inclusion and exclusion criteria and were analyzed ( Figure 1 ). The intervention was an NCA addition in 89 studies (19.6%), a modification of radiation dose/fractionation in 74 studies (16.3%), a modification of cytotoxic regimens in 63 studies (13.9%), a chemotherapy addition in 63 studies (13.9%) and a radiotherapy addition in 48 trials (11.2%). The goal of studies was to prove superiority in 91.6% of trials. Main primary end points were overall survival (46.5%), progression-free survival (20.5%), toxicity (13.9%), local control (10.1%) and disease-free survival (8.4%). Funding sources were not available in 13.2% of publications. Studies characteristics are reported in Table 1 .
Studies characteristics
Patient characteristics
The median number of patients included per study was 256 (Q1-Q3: 130-446; min-max: 19-5318), with a median age of 59 years (Q1-Q3: 55-63; min-max: 7.9-86.3). Median age was not reported in 85 trials (18.7%). Patients were randomized with a locally advanced disease (73.7%), an early stage disease (39.6%), or at a metastatic setting (9.0%). The most analyzed primary locations were head and neck (21.8%), lung (14.3%), breast (10.1%), prostate (9.9%), colorectal cancer (7.5%), brain (7.3%) and cervix (7.0%). Patient characteristics are reported location by location in Table 2 .
Data on treatment
The 454 studies included 977 treatment arms, with 889 arms experiencing radiotherapy. A total of 324 trials (71.4%) studied the association of radiation with other treatments and 130 trials (28.6%) investigated exclusive radiotherapy. A radiation doseescalation was performed in 36 studies (7.9%). Radiation technique was exclusively 3D-conformal radiotherapy in 288 arms (32.4%), a radiation technique association (brachytherapy associated with external beam radiotherapy or 3D conformational radiotherapy associated with SBRT) in 73 arms (8.2%), and exclusively intensity-modulated radiotherapy in 12 arms (1.4%). Different radiation techniques were accepted in 70 arms (7.8%). Radiotherapy technique was not described in 355 arms (39.9%). Normo-fractionation (1.8-2.2 Gy/fraction) was performed in 648 arms (72.9%), hypofractionation in 107 arms (12.0%) and hyperfractionation in 71 arms (8.0%). Normofractionated versus hypo/hyperfractionated programs were compared in 63 studies (13.9%). Radiotherapy characteristics are reported in Table 3 .
Chemotherapy was performed in 257 studies (56.6%), resulting in 444 arms. Chemotherapy was delivered with concurrent radiotherapy in 303 arms (68.2%). Cisplatin (219 arms, 49.3%), 5-fluorouracil (128 arms, 28.8%), carboplatin (49 arms, 11.0%), and etoposide (47 arms, 10.6%) were mainly prescribed. Chemotherapy characteristics are summarized in Table 4 .
An NCA was prescribed in 113 studies (24.9%), resulting in 147 treatment arms. Main NCAs were hormonal interventions (20 arms, 13.6%), targeted therapies (18 arms, 12.2%), and immunotherapies (9 arms, 6.1%). NCA were most of the time concomitantly associated with radiotherapy (124 arms, 84.3%). NCA characteristics are detailed in Table 5 .
Follow-up, toxicities and quality of life
Median follow-up was 50 months (Q1-Q3: 29-73; min-max: 1-127), with 118 studies (26%) not reporting it. Quality of life was evaluated in 118 studies (26.0%). Acute all-grade and acute grade 3-5 toxicities were reported in 225 studies (49.6%) and in 315 studies (69.4%), respectively. Data on late toxicities were reported in 141 studies (31.1%). Data on toxicities are reported in Table 6 .
Discussion
Although analyses of phase I and II radiotherapy trials were previously conducted [6, 7] , the present manuscript is the first analysis of phase III randomized radiotherapy studies. Justifications and limitations of real-world practices in radiation oncology are highlighted.
Radiotherapy RCTs should be considered as recent developments, since the two-thirds were published in the last decade and only 14.3% before 2000. Most of analyzed trials were exclusively based on 3D conformational radiotherapy. Comparison of innovative techniques (IMRT, VMAT, SBRT) versus 3D conformational radiotherapy was rarely performed (<2%). Therefore, efficacy and toxicity results obtained with 3D conformational radiotherapy should be cautiously extrapolated to other techniques in the absence of RCT. For instance, the bath-dose phenomenon (large healthy tissue volume receiving low radiation RCT, randomized controlled trial. are widely used in daily routine have been only been very recently [8] validated with RCTs, or will soon be [9] . Radiation technique comparison was rare (4.8%), most of trial rather testing different global managements of care. Rightly or wrongly, the radiation technique is not expected to produce major variation regarding primary end points, but this assertion is still to be demonstrated. The population included in trials was younger than daily routine patients undergoing radiotherapy [10] , with only 16 RCTs reporting a median age >70 years. Major differences were reported in lung cancer patients (RCTs median age ¼ 63 versus 70 in real-life patients) and in head and neck cancer patients (RTCs median age ¼ 55.5 versus 62 in real-world patients). Extrapolation of studies results in the real-world population might therefore sometimes be questionable [11] . Furthermore, the literature sorely lacks trials studying adapted-to-elderly radiotherapy programs since oncogeriatric scales use does not define new target volumes, new radiation doses/fractionations, or personalized concurrent chemotherapy protocols. Head and neck carcinoma was the most analyzed primary location (21.8%) even though it is only the sixth most common cancer worldwide [12] . The leading place in literature is probably explained by the fact that head and neck is one of the only cancers in which benefits of IMRT [13] , and of concurrent targeted therapy were proven [14] . However, although IMRT proved its superiority over 3D-conformational radiotherapy, most of patients are now treated using VMAT, whose real therapeutic index was recently questioned [15, 16] . This situation highlights the fact that technological progress always remains one step ahead clinical results. This situation is a major problem in good prognoses (breast, prostate, etc.) or rare (cervix, sarcomas, etc.) cancers, since the radiation technique is often considered outdated when definitive results are published. However, without certainty on long-term efficacy and toxicity, innovative radiotherapy techniques must be performed (whenever possible) within the framework of clinical trials.
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Overall survival was often selected as the primary end point (46.5%). Although it is the gold standard, survival assessment requires a large number of patients, a long follow-up and increases the cost of randomized clinical trials [17] . The identification of relevant surrogate markers is probably a major challenge of modern oncology, since future personalized treatment lines will probably differently impact patient overall survival, depending of their genetic alterations [18] . Although the goal of most RCTs was to study the effect of a combination NCA/radiation, more needs to be done, especially regarding the interactions between targeted therapies and radiotherapy. While targeted therapies have been studied in many clinical trials, there is still paucity of data regarding their association with radiotherapy (12.2% of NCA). Numerous trials (>90 in lung cancer) are currently recruiting but an extreme caution is advised while awaiting results [19] . One of the most important challenges of these RCTs is the high-quality reporting of acute and late toxicities. In our analysis, all-grade and grade 3-5 adverse events were only reported in 49.6% and 69.4% of trials, respectively. Worse, late toxicities were reported in 31.1% of RCTs, suggesting that the reporting of adverse events remains highly variable and that standards for reporting need to be improved [20, 21] . To this end, Consolidated Standards of Reporting Trials (CONSORT) statement was developed [22] . Although the quality of reporting in radiation RCTs is poorly described, it is a crucial element to ensure reproducible results [23] [24] [25] . The present analysis revealed that 39.9% of radiotherapy programs were not described and that median follow-up was not reported in 26% of publications. These results were corroborated by other authors, suggesting that that numerous CONSORT items were most of the time not reported in radiation oncology trials [26, 27] . This lack of reporting of radiation details widely hampers the appreciation of the quality of radiation. This point raises serious concern on outcome interpretation since it was demonstrated that deviations from radiation standards on multicenter phase III clinical trials was associated with decreased survival [28, 29] . Therefore, a better reporting of radiation detail is of paramount importance in order to accurately appreciate the quality of radiation, and to be able to critically assess reported trials.
RCTs will (and should) remain a key tool in clinical research. Through a simple portrait of phase III RCTs, the present review suggests that radiotherapy trials must be carefully interpreted since patient population and radiotherapy techniques might differ from daily routine practice, and since reporting quality was often limited. Furthermore, the years to come will probably give birth to a vast possibility of treatment and doses combinations, with different anticancer agents, immune and targeted therapies and radiotherapy techniques [6] . This will probably reduce the possibility to recruit a large number of patients in randomized two-armed trials. In this evolving environment, newer trial designs have already been developed, such as those focused on efficiently assessing targeted interventions for specific pathway or genomic signatures. Regarding radiotherapy, integration of mathematic modelling and radiomics data could be probably integrated in the design of future phase III RCTs in order to increase the statistical power. Adapted and well suited methods should probably be now collectively designed by investigators, physicians, statisticians and methodologists. Let's be up for the challenge of reinventing radiotherapy trials, let's build the future of radiation trials on past evidences.
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